What Is the Optimal Model to Estimate the Benefits of Chemotherapy in Patients With Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer?

被引：1
|
作者：
Ando, Kenju [1 ]
Shimomura, Akihiko [1 ]
Yoshimura, Kenichi [2 ]
Kawamura, Yukino [1 ]
Shimizu, Chikako [1 ]
机构：
[1] Natl Ctr Global Hlth & Med, Dept Breast & Med Oncol, Shinjuku Ku, Tokyo, Japan
[2] Hiroshima Univ Hosp, Med Ctr Translat & Clin Res, Minami Ku, Hiroshima, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 17期
关键词：
WOMEN;
D O I：
10.1200/JCO.21.00178
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1946 / +
页数：3
相关论文
共 50 条
  • [1] What Is the Optimal Model to Estimate the Benefits of Chemotherapy in Patients With Hormone Receptor-Positive, HER2-Negative, NodeNegative Breast Cancer? Reply
    Sparano, Joseph A.
    Crager, Michael R.
    Tang, Gong
    Gray, Robert J.
    Stemmer, Salomon M.
    Shak, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (17) : 1947 - +
  • [2] Chemotherapy use for hormone receptor-positive, node-negative breast cancer
    Hassett, M. J.
    Hughes, M. E.
    Niland, J. C.
    Edge, S. B.
    Theriault, R. L.
    Wong, Y.
    Wilson, J.
    Carter, B. W.
    Blayney, D. W.
    Weeks, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Prognosis prediction with the IHC3 score in patients with node-negative, hormone receptor-positive, HER2-negative early breast cancer
    Seitz, K.
    Goossens, C.
    Huebner, H.
    Gass, P.
    Uhrig, S.
    Heindl, F.
    Emons, J.
    Ruebner, M.
    Anetsberger, D.
    Hartmann, A.
    Beckmann, M. W.
    Erber, R.
    Hack, C. C.
    Fasching, P. A.
    Haeberle, L.
    ESMO OPEN, 2024, 9 (11)
  • [4] Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer
    Rakha, Emad A.
    Agarwal, Devika
    Green, Andrew R.
    Ashankyty, Ibraheem
    Ellis, Ian O.
    Ball, Graham
    Alaskandarany, Mohammed A.
    HISTOPATHOLOGY, 2017, 70 (04) : 622 - 631
  • [5] Chemotherapy Use for Hormone Receptor-Positive, Lymph Node-Negative Breast Cancer
    Hassett, Michael J.
    Hughes, Melissa E.
    Niland, Joyce C.
    Edge, Stephen B.
    Theriault, Richard L.
    Wong, Yu-Ning
    Wilson, John
    Carter, W. Bradford
    Blayney, Douglas W.
    Weeks, Jane C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (34) : 5553 - 5560
  • [6] Immunotherapy for hormone receptor-positive HER2-negative breast cancer
    Cardoso, Fatima
    Hirshfield, Kim M.
    Kraynyak, Kimberly A.
    Tryfonidis, Konstantinos
    Bardia, Aditya
    NPJ BREAST CANCER, 2024, 10 (01)
  • [7] Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial
    Albain, Kathy S.
    Gray, Robert J.
    Makower, Della F.
    Faghih, Amir
    Hayes, Daniel F.
    Geyer, Charles E., Jr.
    Dees, Elizabeth C.
    Goetz, Matthew P.
    Olson, John A., Jr.
    Lively, Tracy
    Badve, Sunil S.
    Saphner, Thomas J.
    Wagner, Lynne, I
    Whelan, Timothy J.
    Ellis, Matthew J.
    Wood, William C.
    Keane, Maccon M.
    Gomez, Henry L.
    Reddy, Pavan S.
    Goggins, Timothy F.
    Mayer, Ingrid A.
    Brufsky, Adam M.
    Toppmeyer, Deborah L.
    Kaklamani, Virginia G.
    Berenberg, Jeffrey L.
    Abrams, Jeffrey
    Sledge, George W., Jr.
    Sparano, Joseph A.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (04): : 390 - 399
  • [8] Patterns of chemotherapy receipt among patients with hormone receptor-positive, HER2-negative breast cancer
    Linnea T. Olsson
    Alina M. Hamilton
    Sarah C. Van Alsten
    Jennifer L. Lund
    Til Stürmer
    Hazel B. Nichols
    Katherine E. Reeder-Hayes
    Melissa A. Troester
    Breast Cancer Research and Treatment, 2024, 204 : 107 - 116
  • [9] Patterns of chemotherapy receipt among patients with hormone receptor-positive, HER2-negative breast cancer
    Olsson, Linnea T.
    Hamilton, Alina M.
    Van Alsten, Sarah C.
    Lund, Jennifer L.
    Sturmer, Til
    Nichols, Hazel B.
    Reeder-Hayes, Katherine E.
    Troester, Melissa A.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 204 (01) : 107 - 116
  • [10] Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: When, why and what?
    Torrisi, Rosalba
    Marrazzo, Emilia
    Agostinetto, Elisa
    De Sanctis, Rita
    Losurdo, Agnese
    Masci, Giovanna
    Tinterri, Corrado
    Santoro, Armando
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 160
12345